{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["von Mollendorf C"],"funding":["World Health Organization","Gavi","Wellcome Trust"],"pagination":["1137-1145"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616686"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(8)"],"pubmed_abstract":["<h4>Objectives</h4>Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. We measured 13-valent PCV (PCV13) effect on different pneumococcal outcomes using diverse studies in Lao People's Democratic Republic.<h4>Methods</h4>Studies included: pre-PCV13 population-based record review of hospitalized childhood pneumonia cases; acute respiratory infection (ARI) study post-PCV13 to demonstrate effectiveness (VE) against hypoxic pneumonia; invasive pneumococcal disease (IPD) surveillance in all ages (2004-2018); carriage studies in children hospitalized with ARI (2013-2019); community carriage surveys pre- and post-PCV13.<h4>Results</h4>Annual pneumonia incidence rate in children pre-PCV13 was 1,530 (95% confidence interval [CI] 1,477-1,584) per 100,000. Adjusted VE against hypoxic pneumonia was 37% (95% CI 6-57%). For IPD, 85% (11/13) of cases were due to vaccine-types pre-PCV13, and 43% (3/7) post-PCV13 in children aged <5 years; for ≥5 years, 61% (27/44) and 42% (17/40), respectively. For ARI cases, adjusted VE for vaccine-type carriage was 39% (95% CI 4-60) in <5 year olds; slightly higher than community surveys (23% [95% CI 4-39%] in 12-23 month olds).<h4>Conclusions</h4>Despite limited baseline data, we found evidence of PCV13 impact on disease and carriage. Our approach could be used in similar settings to augment existing WHO PCV evaluation guidelines."],"journal":["Expert review of vaccines"],"pubmed_title":["Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings."],"pmcid":["PMC7616686"],"funding_grant_id":["001","219762","106698/Z/14/Z"],"pubmed_authors":["Sychareun V","Ortika BD","von Mollendorf C","Lai JYR","Lim R","Mayxay M","Dance DAB","Choummanivong M","Chan J","Satzke C","Dunne EM","Datta SS","Weaver R","Phommachanh S","Nguyen CD","Fox K","Phetsouvanh R","Mulholland KE","Gray A","Russell FM","Moore KA","Vilivong K","Newton PN"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings.","description":"<h4>Objectives</h4>Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. We measured 13-valent PCV (PCV13) effect on different pneumococcal outcomes using diverse studies in Lao People's Democratic Republic.<h4>Methods</h4>Studies included: pre-PCV13 population-based record review of hospitalized childhood pneumonia cases; acute respiratory infection (ARI) study post-PCV13 to demonstrate effectiveness (VE) against hypoxic pneumonia; invasive pneumococcal disease (IPD) surveillance in all ages (2004-2018); carriage studies in children hospitalized with ARI (2013-2019); community carriage surveys pre- and post-PCV13.<h4>Results</h4>Annual pneumonia incidence rate in children pre-PCV13 was 1,530 (95% confidence interval [CI] 1,477-1,584) per 100,000. Adjusted VE against hypoxic pneumonia was 37% (95% CI 6-57%). For IPD, 85% (11/13) of cases were due to vaccine-types pre-PCV13, and 43% (3/7) post-PCV13 in children aged <5 years; for ≥5 years, 61% (27/44) and 42% (17/40), respectively. For ARI cases, adjusted VE for vaccine-type carriage was 39% (95% CI 4-60) in <5 year olds; slightly higher than community surveys (23% [95% CI 4-39%] in 12-23 month olds).<h4>Conclusions</h4>Despite limited baseline data, we found evidence of PCV13 impact on disease and carriage. Our approach could be used in similar settings to augment existing WHO PCV evaluation guidelines.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-03T23:23:52.72Z","creation":"2025-04-03T23:23:52.72Z"},"accession":"S-EPMC7616686","cross_references":{"pubmed":["34378467"],"doi":["10.1080/14760584.2021.1965474"]}}